AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001) (NCT07136727) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)
China5,000 participantsStarted 2025-08-15
Plain-language summary
Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with a definite diagnosis of malignancy by histopathology and/or cytology;
* Age ≥18 years;
* There is no gender limit
* Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ;
* Conscious and able to answer questions and use electronic devices autonomously;
* Patients were able to understand the study and voluntarily sign an informed consent form;
Exclusion Criteria:
* Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme;
* With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness;
* Women during pregnancy or lactation；
* Have participated in other interventional studies in the past 1 month or are currently participating;
* Patients with ECOG ≥ 3 that do not respond to treatment;
* Patients with an expected survival of \< 3 months that do not respond to treatment;
* Cases deemed unsuitable for enrollment by the investigator.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression-free survival (PFS)
Timeframe: 24 months
2
Overall survival (OS）
Timeframe: 24 months
Trial details
NCT IDNCT07136727
SponsorThe First Affiliated Hospital of Xinxiang Medical College